PE20171259A1 - Compuestos - Google Patents
CompuestosInfo
- Publication number
- PE20171259A1 PE20171259A1 PE2017001084A PE2017001084A PE20171259A1 PE 20171259 A1 PE20171259 A1 PE 20171259A1 PE 2017001084 A PE2017001084 A PE 2017001084A PE 2017001084 A PE2017001084 A PE 2017001084A PE 20171259 A1 PE20171259 A1 PE 20171259A1
- Authority
- PE
- Peru
- Prior art keywords
- compound
- ethyl
- methyl
- refers
- kidney disease
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- WPAHVUADNLXSOM-UHFFFAOYSA-N 3-[5-chloro-6-(1-pyridin-2-ylethoxy)-1,2-benzoxazol-3-yl]propanoic acid Chemical compound ClC=1C(=CC2=C(C(=NO2)CCC(=O)O)C=1)OC(C)C1=NC=CC=C1 WPAHVUADNLXSOM-UHFFFAOYSA-N 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 206010033647 Pancreatitis acute Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 201000003229 acute pancreatitis Diseases 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se refiere a un compuesto de formula (I) en la que R1 es heteroarilo opcionalmente sustituido con metilo, etilo, halo o =O; R2 es H, metilo o etilo, o una sal del mismo. Es un compuesto seleccionado el acido 3-(5-cloro-6-(1-(piridin-2-il)etoxi)benzo[d]isoxazol-3-il)propanoico; entre otros. Tambien se refiere a una composicion. Dicho compuesto es un inhibidor de KMO siendo util en el tratamiento de pancreatitis aguda, enfermedad renal cronica, enfermedad renal aguda, entre otros
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201422727 | 2014-12-19 | ||
| GBGB1508866.9A GB201508866D0 (en) | 2015-05-22 | 2015-05-22 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20171259A1 true PE20171259A1 (es) | 2017-08-28 |
Family
ID=54850210
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017001084A PE20171259A1 (es) | 2014-12-19 | 2015-12-17 | Compuestos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US9932328B2 (es) |
| EP (1) | EP3233844B1 (es) |
| JP (1) | JP6644790B2 (es) |
| KR (1) | KR102557791B1 (es) |
| CN (1) | CN107108594B (es) |
| AU (1) | AU2015367396C1 (es) |
| BR (1) | BR112017013193B1 (es) |
| CA (1) | CA2969385C (es) |
| CL (1) | CL2017001549A1 (es) |
| CO (1) | CO2017005872A2 (es) |
| CR (1) | CR20170261A (es) |
| DO (1) | DOP2017000141A (es) |
| EA (1) | EA033632B1 (es) |
| ES (1) | ES2737893T3 (es) |
| IL (1) | IL252155B (es) |
| JO (1) | JO3656B1 (es) |
| MX (1) | MX373649B (es) |
| MY (1) | MY201861A (es) |
| NZ (1) | NZ732002A (es) |
| PE (1) | PE20171259A1 (es) |
| PH (1) | PH12017500993B1 (es) |
| SG (1) | SG11201703807VA (es) |
| TW (1) | TWI698433B (es) |
| UA (1) | UA120381C2 (es) |
| UY (1) | UY36451A (es) |
| WO (1) | WO2016097144A1 (es) |
| ZA (1) | ZA201702918B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ732002A (en) * | 2014-12-19 | 2023-07-28 | Univ Court Univ Of Edinburgh | 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors |
| KR101684053B1 (ko) * | 2015-01-20 | 2016-12-08 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9720899D0 (en) * | 1997-10-01 | 1997-12-03 | Pharmacia & Upjohn Spa | Condensed heterocyclic compounds |
| US7622495B2 (en) * | 2006-10-03 | 2009-11-24 | Neurim Pharmaceuticals (1991) Ltd. | Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents |
| JP2010527965A (ja) * | 2007-05-24 | 2010-08-19 | ノイロサーチ アクティーゼルスカブ | 例えば呼吸器疾患、てんかん及び痙攣の治療のためのカリウムチャネル調節剤としてのベンゾイソオキサゾール誘導体 |
| US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8691824B2 (en) * | 2008-08-04 | 2014-04-08 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| NZ601547A (en) * | 2010-01-25 | 2014-04-30 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| CN103827095A (zh) * | 2011-08-30 | 2014-05-28 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
| GB201322512D0 (en) * | 2013-12-19 | 2014-02-05 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| NZ732002A (en) * | 2014-12-19 | 2023-07-28 | Univ Court Univ Of Edinburgh | 3-(6-alkoxy-5-chlorobenzo[d]isoxazol-3-yl)propanoic acid useful as kynurenine monooxygenase inhibitors |
-
2015
- 2015-12-17 NZ NZ732002A patent/NZ732002A/en unknown
- 2015-12-17 BR BR112017013193-5A patent/BR112017013193B1/pt active IP Right Grant
- 2015-12-17 CR CR20170261A patent/CR20170261A/es unknown
- 2015-12-17 JO JOP/2015/0324A patent/JO3656B1/ar active
- 2015-12-17 PE PE2017001084A patent/PE20171259A1/es unknown
- 2015-12-17 MY MYPI2017702244A patent/MY201861A/en unknown
- 2015-12-17 EA EA201791402A patent/EA033632B1/ru not_active IP Right Cessation
- 2015-12-17 UY UY0001036451A patent/UY36451A/es active IP Right Grant
- 2015-12-17 TW TW104142406A patent/TWI698433B/zh active
- 2015-12-17 ES ES15810681T patent/ES2737893T3/es active Active
- 2015-12-17 CN CN201580068887.0A patent/CN107108594B/zh active Active
- 2015-12-17 JP JP2017532625A patent/JP6644790B2/ja active Active
- 2015-12-17 KR KR1020177016276A patent/KR102557791B1/ko active Active
- 2015-12-17 WO PCT/EP2015/080221 patent/WO2016097144A1/en not_active Ceased
- 2015-12-17 UA UAA201707042A patent/UA120381C2/uk unknown
- 2015-12-17 EP EP15810681.5A patent/EP3233844B1/en active Active
- 2015-12-17 SG SG11201703807VA patent/SG11201703807VA/en unknown
- 2015-12-17 MX MX2017008069A patent/MX373649B/es active IP Right Grant
- 2015-12-17 PH PH1/2017/500993A patent/PH12017500993B1/en unknown
- 2015-12-17 AU AU2015367396A patent/AU2015367396C1/en active Active
- 2015-12-17 US US15/537,805 patent/US9932328B2/en active Active
- 2015-12-17 CA CA2969385A patent/CA2969385C/en active Active
-
2017
- 2017-04-26 ZA ZA2017/02918A patent/ZA201702918B/en unknown
- 2017-05-08 IL IL252155A patent/IL252155B/en active IP Right Grant
- 2017-06-14 DO DO2017000141A patent/DOP2017000141A/es unknown
- 2017-06-14 CO CONC2017/0005872A patent/CO2017005872A2/es unknown
- 2017-06-15 CL CL2017001549A patent/CL2017001549A1/es unknown
-
2018
- 2018-02-20 US US15/900,043 patent/US10273232B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR089818A1 (es) | Inhibidor de la quinasa que regula la señal de la apoptosis | |
| CO2017002714A2 (es) | Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo | |
| AR110381A2 (es) | Inhibidores biarilo de tirosina cinasa de bruton | |
| BR112017006253A2 (pt) | novos compostos | |
| DOP2015000251A (es) | Derivados de naftiridina utiles como antagonistas de la alfa-v-beta-6 integrina | |
| AR094918A1 (es) | Compuestos de tetrahidropirrolotiazina como inhibidores de bace | |
| CL2016001458A1 (es) | Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo. | |
| PE20160862A1 (es) | Polimorfo de los inhibidores de la syk | |
| JO3392B1 (ar) | مركبات عطرية حلقية غير متجانسة كمركبات مضادة للالتهاب | |
| PE20140831A1 (es) | Nuevo derivado de 1,2,3,4-tetrahidroquinolina util para el tratamiento de diabetes | |
| AR098274A1 (es) | Inhibidor de grelina o-acil transferasa | |
| AR095727A1 (es) | Preparación de intermediarios de pirimidina | |
| AR095097A1 (es) | Compuestos de fenoxietoxi | |
| EA201691983A1 (ru) | Пиридин-2-амиды, пригодные в качестве агонистов cb2 | |
| AR105821A1 (es) | COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T | |
| CY1122506T1 (el) | Κρυσταλλικη μορφη της ενωσης (s)-3-{4-[5-(2-κυκλοπεντυλ-6- μεθοξυ- πυριδιν-4- υλ)-[1,2,4]οξαδιαζολ-3- υλ]-2- αιθυλ-6-μεθυλ- φαινοξυ}- προπανο-1,2- διολη | |
| CL2018001067A1 (es) | Compuesto piranodipiridínico. | |
| ES2571577T3 (es) | Derivados novedosos de morfolinilo útiles como inhibidores de MOGAT-2 | |
| EA201790687A1 (ru) | Хинолинкарбоксамиды для применения в лечении множественной миеломы | |
| UY34943A (es) | Composiciones herbicidas que comprenden ácido 4-amino-3-cloro-5-fluoro-6-(4-cloro-2-fluoro-3-metoxifenilo)piridina-2-carboxílico o un derivado del mismo y un sulfonilaminocarboniltriazolinona. | |
| PE20171259A1 (es) | Compuestos | |
| AR103354A1 (es) | INHIBIDORES DE 3-FLUORO-BENZONITRILO DE 11-b-HIDROXILASA | |
| MX377963B (es) | Composición acuosa. | |
| PH12017500492A1 (en) | Crystalline bace inhibitors | |
| AR098134A1 (es) | Compuestos de urea |